# Alaunos Therapeutics > immuno-oncology company **Wikidata**: [Q113504139](https://www.wikidata.org/wiki/Q113504139) **Source**: https://4ort.xyz/entity/alaunos-therapeutics ## Summary Alaunos Therapeutics is a public immuno-oncology company founded in 2004 and headquartered in Houston, specializing in cell therapy approaches to cancer treatment. The company operates as Alaunos Therapeutics, Inc. and trades publicly under the central index key 0001107421, maintaining an English-language corporate presence at https://alaunos.com/. ## Key Facts - Founded in 2004 as a biotechnology enterprise focused on cancer immunotherapy. - Incorporated as Alaunos Therapeutics, Inc., operating under the trade name "Alaunos." - Classified as a public company, offering securities for sale to the general public. - Headquartered in Houston, establishing its primary corporate operations in Texas. - Central Index Key (CIK) identifier is 0001107421 for SEC filing purposes. - Official website is https://alaunos.com/, with English as its primary language. - Operates exclusively within the immuno-oncology therapeutic area. - Develops cell therapy technologies as its core scientific and commercial focus. ## FAQs **What is Alaunos Therapeutics?** Alaunos Therapeutics is a publicly traded biotechnology company established in 2004 that develops immuno-oncology treatments, specifically focusing on cell therapy platforms to combat cancer. **What specific field does Alaunos Therapeutics work in?** The company concentrates on immuno-oncology, which involves harnessing the immune system to fight cancer, and specializes in cell therapy modalities that engineer or utilize living cells as therapeutic agents. **Where is Alaunos Therapeutics located?** Alaunos Therapeutics maintains its corporate headquarters in Houston, Texas, serving as the central hub for its research, development, and administrative operations. **Is Alaunos Therapeutics publicly traded?** Yes, Alaunos Therapeutics is a public company, meaning its securities are available for purchase by the general public and it is registered with the SEC under CIK 0001107421. **What are the alternative names for Alaunos Therapeutics?** The company is formally incorporated as Alaunos Therapeutics, Inc. and commonly referred to by its shortened trade name "Alaunos" in business and scientific contexts. ## Why It Matters Alaunos Therapeutics represents a critical component of the modern biotechnology ecosystem, operating at the intersection of immunology and oncology to address unmet medical needs in cancer treatment. As a public company since its 2004 inception, it provides investment opportunities in the high-growth cell therapy sector while advancing scientific platforms that could potentially transform how cancers are treated. Its Houston headquarters positions it within a major American biomedical corridor, facilitating access to clinical research networks, manufacturing infrastructure, and scientific talent. The company's focus on immuno-oncology cell therapy places it in a therapeutic category that has demonstrated breakthrough potential for patients who have exhausted conventional treatment options, contributing to the broader movement toward personalized and living-cell-based medicines that may offer durable responses and improved survival outcomes. ## Notable For - Being a publicly traded immuno-oncology company since 2004, providing transparency and investment access in the specialized cell therapy sector. - Operating under dual identity as both "Alaunos Therapeutics, Inc." (legal entity) and "Alaunos" (commercial brand), reflecting common biotechnology industry naming conventions. - Maintaining a Houston headquarters, distinguishing it from coastal biotechnology clusters while accessing Texas's growing life sciences ecosystem. - Holding SEC Central Index Key 0001107421, enabling regulatory compliance and public financial disclosure. - Focusing exclusively on cell therapy within immuno-oncology, a narrow but high-impact specialization requiring advanced manufacturing and clinical development capabilities. ## Body ### Corporate Identity and Structure Alaunos Therapeutics operates as a public company under its formal legal name, Alaunos Therapeutics, Inc., while conducting business and communications under the abbreviated trade name "Alaunos." This dual-naming approach reflects common practice in the biotechnology industry, where lengthy corporate names are streamlined for branding and market recognition. The company's public status means its ownership is distributed among general public shareholders who purchase its securities, distinguishing it from privately held biotechnology firms that rely on venture capital or private equity funding. As a public entity, Alaunos Therapeutics is subject to Securities and Exchange Commission (SEC) regulations and maintains transparency through mandatory financial reporting, with its unique Central Index Key (CIK) number 0001107421 serving as its permanent identifier in federal filings. ### Foundation and Timeline The company was founded in 2004, establishing its presence in the biotechnology sector during a period of growing interest in immunotherapy approaches to cancer treatment. This founding date places Alaunos among a generation of immuno-oncology companies that emerged in the early 2000s, preceding the modern checkpoint inhibitor revolution while contributing to foundational cell therapy research. Nearly two decades of operation suggests institutional stability and a sustained commitment to its therapeutic platform, having navigated multiple phases of clinical development, financing cycles, and evolving regulatory landscapes for cell-based therapies. ### Geographic Presence and Operations Alaunos Therapeutics is headquartered in Houston, Texas, a strategic location that provides access to the Texas Medical Center—the world's largest medical complex—along with specialized biotechnology manufacturing capabilities and a growing pool of scientific talent. Houston's lower operational costs compared to traditional biotech hubs like Boston or San Francisco may offer competitive advantages in capital-intensive cell therapy development. The headquarters location serves as the company's primary center for executive leadership, research and development coordination, regulatory affairs, and corporate administration, while likely maintaining relationships with clinical trial sites and manufacturing partners across broader geographic regions. ### Therapeutic Focus and Scientific Domain The company operates exclusively within immuno-oncology, a specialized branch of oncology that leverages the patient's immune system to recognize and eliminate cancer cells. Within this domain, Alaunos Therapeutics specifically concentrates on cell therapy, an advanced modality that involves extracting, modifying, and reintroducing living cells to create therapeutic effects. This focus encompasses technologies such as CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, or other engineered cell platforms that require sophisticated manufacturing processes, including cell collection, genetic modification, expansion in bioreactors, and cryopreservation for patient administration. The cell therapy specialization demands expertise in vector development, Good Manufacturing Practice (GMP) compliance, supply chain logistics for living products, and complex clinical trial design. ### Digital Presence and Communication Alaunos Therapeutics maintains an English-language corporate website at https://alaunos.com/, serving as its primary digital interface for investors, healthcare professionals, patients, and potential partners. The website likely contains sections for corporate governance, pipeline updates, SEC filings, clinical trial information, and news releases. The choice of English as the sole language reflects the company's primary focus on U.S. capital markets and regulatory pathways, though public companies often include multilingual support for global clinical trials or international partnerships. The domain name "alaunos.com" provides a concise, brand-aligned web identity that matches its trade name for consistent market recognition. ### Regulatory and Financial Framework As a public company with CIK 0001107421, Alaunos Therapeutics participates in the regulated securities market, filing quarterly reports (10-Q), annual reports (10-K), and proxy statements that disclose its financial condition, pipeline progress, and risk factors to investors. This public disclosure regime creates accountability and enables stakeholders to track its research and development expenditures, cash runway, clinical trial milestones, and commercialization progress. The central index key serves as a permanent identifier across all SEC filings, allowing researchers, investors, and regulators to retrieve the company's complete regulatory history through the EDGAR database, providing transparency into its corporate actions, leadership changes, and strategic pivots since its public registration.